Rallybio Corp RLYB
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-29 |
| Shares Out. | 5,300,000 |
| Website | rallybio.com/ ↗ |
| Phone | 12038593820 |
| Employees | 9 |
| Revenue | $212,000 |
| Gross Profit | $212,000 |
| Net Income | -$8.3M |
| Total Assets | $54.5M |
| Total Liabilities | $4.2M |
| Equity | $50.3M |
About Rallybio Corp
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Rallybio Corp is a publicly traded company under the ticker symbol RLYB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-07-01)